Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - SELLAS Life Sciences Group, Inc. | b87288exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 11, 2011
RXI PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware | 001-33958 | 20-8099512 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
60 Prescott Street,
Worcester, Massachusetts
01605
Worcester, Massachusetts
01605
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area code: (508) 767-3861
Not Applicable
Former name or former address, if changed since last report
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 | Entry into a Material Definitive Agreement |
On July 11, 2011, RXi Pharmaceuticals Corporation (we, us, our and the Company)
entered into an exclusive license agreement with The Henry M. Jackson Foundation for the
Advancement of Military Medicine, Inc. which we refer to as HJF, under which we acquired
additional NeuVax-related technologies. The technologies include, among other rights, exclusive
worldwide rights to use our NeuVax breast cancer vaccine product candidate in combination with
trastuzumab (Herceptin®; Genentech/Roche) and for use in low-to-intermediate HER2+ breast cancer
patients not eligible for Herceptin therapy. These uses are covered by pending U.S. and foreign
patent applications.
NeuVax was discovered by The M. D. Anderson Cancer Center, or MDACC, and HJF and originally
licensed by us from them. Under the license agreement, MDACC and HJF received an upfront payment
from us and will be entitled to future milestone payments and to royalties with respect to product
sales.
Item 8.01 | Other Events |
On July 13, 2011, we issued a press release announcing the license agreement. A copy of the
press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 | Exhibits |
(d) | Exhibits |
There is filed as part of this report the exhibit listed on the accompanying Index to
Exhibits, which information is incorporated herein by reference.
1
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 14, 2011 | RXI PHARMACEUTICALS CORPORATION |
|||
By: | /s/ Mark J. Ahn | |||
Mark J. Ahn | ||||
President and Chief Executive Officer |
2
Index to Exhibits
Exhibit No. | Description | |||
99.1 | Press release of RXi Pharmaceuticals Corporation issued on July 13, 2011. |
3